The U.S. Food and Drug Administration has approved application ANDA077076, submitted by Bedford, for Lorazepam injectable products.
The approval covers two injectable dosage strengths: 2 mg/mL (product number 001) and 4 mg/mL (product number 002). Both products are currently marked as discontinued in the FDA’s records. The original submission (submission number 1) received approval on July 13, 2005.
Cập nhật pháp chế27 thg 9, 2026•1 phút đọc
FDA Approves ANDA077076 for Lorazepam Injectable Products
FDA approved ANDA077076 submitted by Bedford for Lorazepam injectable products (2 mg/mL and 4 mg/mL), both listed as discontinued.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá